In last trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 3.9 million shares changing hands with its beta currently measuring 0.60. Company’s recent per share price level of $1.38 trading at $0.09 or 6.98% at ring of the bell on the day assigns it a market valuation of $254.03M. That closing price of NKTR’s stock is at a discount of -39.86% from its 52-week high price of $1.93 and is indicating a premium of 70.29% from its 52-week low price of $0.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.14 million shares which gives us an average trading volume of 977.36K if we extend that period to 3-months.
For Nektar Therapeutics (NKTR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ:NKTR) trade information
Upright in the green during last session for gaining 6.98%, in the last five days NKTR remained trading in the green while hitting it’s week-highest on Monday, 10/14/24 when the stock touched $1.38 price level, adding 0.72% to its value on the day. Nektar Therapeutics’s shares saw a change of 144.25% in year-to-date performance and have moved 6.15% in past 5-day. Nektar Therapeutics (NASDAQ:NKTR) showed a performance of 6.15% in past 30-days. Number of shares sold short was 7.31 million shares which calculate 8.5 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18.5 to the stock, which implies a rise of 92.54% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -334.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of -334.78% for stock’s current value.
Nektar Therapeutics (NKTR) estimates and forecasts
Statistics highlight that Nektar Therapeutics is scoring comparatively higher than the scores of other players of the relevant industry. The company added 2.22% of value to its shares in past 6 months, showing an annual growth rate of 41.38% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
In 2024, company’s earnings growth rate is likely to be around 45.11% while estimates for its earnings growth in next 5 years are of -7.30%.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders are in possession of 1.06% of company’s total shares while institution are holding 74.01 percent of that, with stock having share float percentage of 74.80%. Investors also watch the number of corporate investors in a company very closely, which is 74.01% institutions for Nektar Therapeutics that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at NKTR for having 17.88 million shares of worth $22.17 million. And as of 2024-06-30, it was holding 9.1789 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 15.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7823 of outstanding shares, having a total worth of $18.79 million.
